Abstract:Abstract Background During the coronavirus disease 2019 (COVID-19) pandemic, the simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ) and Influenza A, and Influenza B viruses is essential for rapid differential diagnosis in patients with similar symptoms, especially during “ flu season” in the post-pandemic era. So far, several multiplex methods have been approved for the simultaneous detection of SARS-CoV-2, Influenza A, and Influenza B . However, due to the rapid mutation rate of the SARS-CoV-2 genome and the emergence of new variants, existing methods must be improved and updated. Methods To identify a highly conserved region in the SARS-CoV-2 N-gene , a genomic survey was performed to increase the sensitivity and specificity of primer and probe sets targeting the SARS-CoV-2 genome. The 95% LLOD (95% lower limits of detection) were calculated by probit analysis. A total of 70 predetermined clinical samples using singleplex RT-qPCR assays, were included. The clinical performance of the multiplex RT-qPCR assay was determined and compared with a commercial multiplex kit. The Cohen’s kappa coefficient, P -value (McNemar’s test), Passing-Bablok regression, and Bland Altman agreement analysis were determined to monitor the agreement of the assays. Results The novel SARS-CoV-2 primer and probe set designed in this assay was able to detect all variants of concern (VOCs) and variants of interest (VOIs) with high analytical and clinical performance. The 95% LLOD for the multiplex RT-qPCR was 20 copies per reaction for the N gene of SARS-CoV-2 , 2 copies per reaction for M1 gene of Influenza A and NS1 gene of Influenza B . The diagnostic sensitivity of the multiplex RT-qPCR was 94.4%, 93.7%, and 100% for the detection of SARS-CoV-2 , Influenza A , and Influenza B genomes, respectively. Moreover, the specificity was identical (100%) in both assays. According to the agreement analysis results, there was no statistical difference between our multiplex assay and the commercial kit. Conclusions In this study, we developed a novel in-house made multiplex RT-qPCR assay, with high sensitivity, specificity, and reliability for the diagnosis of SARS-CoV-2 infection in clinical samples. This is valuable during Influenza seasons when influenza co-circulates with SARS-CoV-2, as it saves costs, time, and thus specific and timely treatment of patients.

Development of a Rapid Automated Influenza A, Influenza B, and Respiratory Syncytial Virus A/B Multiplex Real-Time RT-PCR Assay and Its Use During the 2009 H1N1 Swine-Origin Influenza Virus Epidemic in Milwaukee, Wisconsin

Rapid Semiautomated Subtyping of Influenza Virus Species During the 2009 Swine Origin Influenza A H1N1 Virus Epidemic in Milwaukee, Wisconsin.

Detection of Respiratory Virus by Multiplex Real-Time RT-PCR Assay

Rapid Multiplex Reverse Transcription-Pcr Typing of Influenza A and B Virus, and Subtyping of Influenza A Virus into H1, 2, 3, 5, 7, 9, N1 (human), N1 (animal), N2, and N7, Including Typing of Novel Swine Origin Influenza A (h1n1) Virus, During the 2009 Outbreak in Milwaukee, Wisconsin

A SYBR Green I real-time RT-PCR assay for detection and differentiation of influenza A(H1N1) virus in swine populations.

Rapid Detection of Influenza A Viruses Using a Real-Time Reverse Transcription Recombinase-Aided Amplification Assay.

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

Simultaneous detection of influenza A, influenza B, and respiratory syncytial viruses and subtyping of influenza A H3N2 virus and H1N1 (2009) virus by multiplex real-time PCR.

Development and Comparison of Molecular Assays for the Rapid Detection of the Pandemic Influenza A (H1N1) 2009 Virus

Real-Time Detection of Influenza A, Influenza B, and Respiratory Syncytial Virus A and B in Respiratory Specimens by Use of Nanoparticle Probes

Introduction of a Novel Swine-Origin Influenza A (H1N1) Virus into Milwaukee, Wisconsin in 2009

Parallel Validation of Three Molecular Devices for Simultaneous Detection and Identification of Influenza A and B and Respiratory Syncytial Viruses

[Development of Single-Tube Multiplex Real-Time PCR for Simultaneous Detection of Novel Influenza A H1N1 and Human Seasonal Influenza A H1N1 and H3N2 Virus].

Discriminating North American Swine Influenza Viruses with a Portable, One-Step, Triplex Real-Time RT-PCR Assay, and Portable Sequencing

Development of a robust TaqMan probe-based one-step multiplex RT-qPCR for simultaneous detection of SARS-CoV-2 and Influenza A/B viruses

A Rapid On-Site Assay for the Detection of Influenza A by Capillary Convective PCR

Comparative Measurements of Pandemic 2009 Influenza A (H1N1) Using Multiplex RT-PCR and 2 Real-Time RT-PCR Assays

Development of a Novel Multiplex PCR Method for the Rapid Detection of SARS-CoV-2, Influenza A Virus, and Influenza B Virus

Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform

Analytical and clinical validation of a novel, laboratory-developed, modular multiplex-PCR panel for fully automated high-throughput detection of 16 respiratory viruses